Specialty Pharmacy

Tonsillectomy was associated with an almost tripled relative risk for upper respiratory diseases, including asthma, influenza, pneumonia, and chronic obstructive pulmonary disorder.

Top news of the day from across the health care landscape

Phase 3 data show that ocrelizumab (Ocrevus) may delay the progression of disability, such as the need for a wheelchair, in patients with primary progressive multiple sclerosis (PPMS).

The label update includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.

Quizartinib has prolonged survival in patients with a rare and deadly form of acute myeloid leukemia.

Researchers investigated whether high body mass index is a risk factor not only for a greater risk of multiple sclerosis, but also for advancing to the secondary progressive stage of the disease.

A form of artificial intelligence known as a deep learning convolutional neural network outperformed dermatologists in diagnosing malignant melanomas.

Top news of the day from across the health care landscape

Researchers identified a promising biomarker for the PARP-inhibitor sensitivity in small cell lung cancer, which may help in determining the appropriate treatment for select patients.

Using gene editing to remove CD33, a protein targeted to treat acute myeloid leukemia with chimeric antigen receptor (CAR) T cells, from healthy stem cells could reduce toxicity experienced by CAR T-cell therapy.

Researchers identified a primary mechanism of inflammatory demyelination in the central nervous system during multiple sclerosis, which may lead to new therapeutic approaches.

Top news of the day from across the health care landscape

Matthew Hughes, director of Business Development for the Accreditation Commission for Health Care (ACHC), discusses how the accreditation process carries benefits for stakeholders across the specialty pharmacy space.

Researchers aimed to assess the relationship between fatigue in multiple sclerosis and inflammatory or other immunomediated markers.

Top news of the day from across the health care landscape

A retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS)

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Timolol eyedrops may have a potential role in managing acute migraine for some patients.

In response to the Trump Administration’s drug pricing blueprint, the American College of Rheumatology issued a set of policy principles on drug prices and access to rheumatology treatment.

A 2-part trial shows a new antibody that suppresses HIV when combined with antiretroviral therapy (ART).

Despite universal access to care afforded to US military service members, there is a need to improve and expand access to PrEP for those patients at highest risk for HIV infection.

Top news of the day from across the health care landscape

Officials with the FDA have approved bevacizumab (Avastin, Genentech) in combination with carboplatin and paclitaxel for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Pembrolizumab (Keytruda, Merck) gained FDA approval for 2 new oncology indications.

On National HIV Testing Day, which takes place on June 27, Walgreens and Greater Than AIDS will team up with over 200 health and community organizations to provide free HIV testing and information at Walgreens stores in over 180 cities.

Ocrelizumab showed a sustained reduction in underlying disease activity and improved cognitive function in patients with relapsing multiple sclerosis.

Top news of the day from across the health care landscape

The study aimed to analyze whether age, gender, socioeconomic factors, comorbidity, and medication may affect the risk of lung cancer in patients with COPD.

The Working Group examined the insulin supply chain and the factors that impact the costs of and access to insulin products.